Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly pointed to ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna (NASDAQ:MRNA) shares continued to tumble in the pre-market on Friday as J.P ...

today announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline at its annual R&D Day event. The updates include data readouts in the Company ...